Shots: The P-III BLISS-LN study involves assessing of IV belimumab 10 mg/kg + standard therapy vs PBO in 448 patients with active lupus nephritis for 104 wks. P-III BLISS-LN study […]readmore
Tags : IV
Shots: The study involves assessing multistem therapy (IV)(n=20) vs PBO (n=10) in patients with ARDS for 28 days Study results: Lower mortality (LM)(25% vs 40%); VF days (12.9 vs 9.2); […]readmore
Shots: The approval is based on P-III HELP study results assessing Takhzyro (300 mg q2w, 300 mg q4w, 150 mg q4w) vs PBO in 125 patients with HAE aged ≥12 […]readmore